Business
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), announced today one oral and two poster presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) taking place in Copenhagen. The presentations will highlight new
About this update from Acumen Pharmaceuticals, Inc.
[{"type":"image","alt":"Acumen Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Acumen Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5J.4IvnfhFM_bTHIo4TE3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879","width":300,"height":62}},"lazy":false},{"type":"text","content":"NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), announced today one oral and two poster presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) taking place in Copenhagen. The presentations will highlight new data regarding enhanced brain delivery (EBD™) of sabirnetug, sabirnetug biomarker treatment responses, and the development of new AβO-targeting antibodies. The conference will be held in-person and online March 17-21, 2026.","length":724,"tagName":"p"},{"type":"text","content":"“The data we’re presenting reflects our dedication to finding better solutions for Alzheimer’s patients and their families,” said Jim Doherty, President and Chief Development Officer of Acumen. “By exploring enhanced brain delivery methods and developing more selective antibodies, we’re working toward treatments that could potentially improve effectiveness and safety, while expanding convenience and supporting a wider range of people impacted by Alzheimer’s disease.”","length":471,"tagName":"p"},{"type":"text","content":"Acumen’s presentation details are as follows:","length":45,"tagName":"p"},{"type":"text","content":"Oral Presentation","length":17,"tagName":"p"},{"type":"text","content":"Title: Enhanced Brain Delivery of Sabirnetug After Fusion with an Anti-Transferrin Receptor Antibody Fragment in a Mouse Model of Alzheimer’s Disease","length":149,"tagName":"p"},{"type":"text","content":"Date/Time: Saturday, March 21 at 8:40 – 10:40 a.m. CETSession Name: 5940 - RESTORING NEURAL RESILIENCE IN ALS AND ALZHEIMER’S DISEASE (ID 21...